Evaluation of a commercial recombinant tissue-type plasminogen activator preparation in the subretinal space of the cat

J. D. Benner, Lawrence S Morse, C. A. Toth, M. B. Landers, Leonard M Hjelmeland

Research output: Contribution to journalArticle

28 Citations (Scopus)

Abstract

To explore the feasibility of using human recombinant tissue-type plasminogen activator in the management of subretinal hemorrhage, we examined the toxic effects of a commercial preparation of human recombinant tissue- type plasminogen activator in the subretinal space of the holangiotic retina of the cat. Various concentrations of human recombinant tissue-type plasminogen activator and controls were infused into the subretinal space with a glass micropipette (40- to 60-μm tip) to form a retinal bleb. Concentrations from 2.5 mg/L to 200 mg/L were well tolerated without ultrastructural toxic effects, while 1000 mg/L of human recombinant tissue- type plasminogen activator caused severe, irreversible toxic effects to the photoreceptor-retinal pigment epithelium complex. This toxic effect appeared to be due to the carrier vehicle rather than the human recombinant tissue- type plasminogen activator protein itself. Our results demonstrate that commercially prepared human recombinant tissue-type plasminogen activator can be safely used in the subretinal space of the cat with the range necessary for fibrinolysis.

Original languageEnglish (US)
Pages (from-to)1731-1736
Number of pages6
JournalArchives of Ophthalmology
Volume109
Issue number12
StatePublished - 1991

Fingerprint

Tissue Plasminogen Activator
Cats
Poisons
Retinal Pigment Epithelium
Fibrinolysis
Blister
Glass
Retina
Hemorrhage
Proteins

ASJC Scopus subject areas

  • Ophthalmology

Cite this

Evaluation of a commercial recombinant tissue-type plasminogen activator preparation in the subretinal space of the cat. / Benner, J. D.; Morse, Lawrence S; Toth, C. A.; Landers, M. B.; Hjelmeland, Leonard M.

In: Archives of Ophthalmology, Vol. 109, No. 12, 1991, p. 1731-1736.

Research output: Contribution to journalArticle

@article{a8cb6e766285402ea1afe5ab4a169005,
title = "Evaluation of a commercial recombinant tissue-type plasminogen activator preparation in the subretinal space of the cat",
abstract = "To explore the feasibility of using human recombinant tissue-type plasminogen activator in the management of subretinal hemorrhage, we examined the toxic effects of a commercial preparation of human recombinant tissue- type plasminogen activator in the subretinal space of the holangiotic retina of the cat. Various concentrations of human recombinant tissue-type plasminogen activator and controls were infused into the subretinal space with a glass micropipette (40- to 60-μm tip) to form a retinal bleb. Concentrations from 2.5 mg/L to 200 mg/L were well tolerated without ultrastructural toxic effects, while 1000 mg/L of human recombinant tissue- type plasminogen activator caused severe, irreversible toxic effects to the photoreceptor-retinal pigment epithelium complex. This toxic effect appeared to be due to the carrier vehicle rather than the human recombinant tissue- type plasminogen activator protein itself. Our results demonstrate that commercially prepared human recombinant tissue-type plasminogen activator can be safely used in the subretinal space of the cat with the range necessary for fibrinolysis.",
author = "Benner, {J. D.} and Morse, {Lawrence S} and Toth, {C. A.} and Landers, {M. B.} and Hjelmeland, {Leonard M}",
year = "1991",
language = "English (US)",
volume = "109",
pages = "1731--1736",
journal = "JAMA Ophthalmology",
issn = "2168-6165",
publisher = "American Medical Association",
number = "12",

}

TY - JOUR

T1 - Evaluation of a commercial recombinant tissue-type plasminogen activator preparation in the subretinal space of the cat

AU - Benner, J. D.

AU - Morse, Lawrence S

AU - Toth, C. A.

AU - Landers, M. B.

AU - Hjelmeland, Leonard M

PY - 1991

Y1 - 1991

N2 - To explore the feasibility of using human recombinant tissue-type plasminogen activator in the management of subretinal hemorrhage, we examined the toxic effects of a commercial preparation of human recombinant tissue- type plasminogen activator in the subretinal space of the holangiotic retina of the cat. Various concentrations of human recombinant tissue-type plasminogen activator and controls were infused into the subretinal space with a glass micropipette (40- to 60-μm tip) to form a retinal bleb. Concentrations from 2.5 mg/L to 200 mg/L were well tolerated without ultrastructural toxic effects, while 1000 mg/L of human recombinant tissue- type plasminogen activator caused severe, irreversible toxic effects to the photoreceptor-retinal pigment epithelium complex. This toxic effect appeared to be due to the carrier vehicle rather than the human recombinant tissue- type plasminogen activator protein itself. Our results demonstrate that commercially prepared human recombinant tissue-type plasminogen activator can be safely used in the subretinal space of the cat with the range necessary for fibrinolysis.

AB - To explore the feasibility of using human recombinant tissue-type plasminogen activator in the management of subretinal hemorrhage, we examined the toxic effects of a commercial preparation of human recombinant tissue- type plasminogen activator in the subretinal space of the holangiotic retina of the cat. Various concentrations of human recombinant tissue-type plasminogen activator and controls were infused into the subretinal space with a glass micropipette (40- to 60-μm tip) to form a retinal bleb. Concentrations from 2.5 mg/L to 200 mg/L were well tolerated without ultrastructural toxic effects, while 1000 mg/L of human recombinant tissue- type plasminogen activator caused severe, irreversible toxic effects to the photoreceptor-retinal pigment epithelium complex. This toxic effect appeared to be due to the carrier vehicle rather than the human recombinant tissue- type plasminogen activator protein itself. Our results demonstrate that commercially prepared human recombinant tissue-type plasminogen activator can be safely used in the subretinal space of the cat with the range necessary for fibrinolysis.

UR - http://www.scopus.com/inward/record.url?scp=0026409936&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0026409936&partnerID=8YFLogxK

M3 - Article

C2 - 1841586

AN - SCOPUS:0026409936

VL - 109

SP - 1731

EP - 1736

JO - JAMA Ophthalmology

JF - JAMA Ophthalmology

SN - 2168-6165

IS - 12

ER -